CoChat

Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge

Open access
Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Follmann, Dean, Neuzil, Kathleen M., August, Allison, Clouting, Heather, Fortier, Gabrielle, Deng, Weiping, Han, Shu, Zhao, Xiaoping, Leav, Brett, Talarico, Carla, Girard, Bethany, Paila, Yamuna D., Tomassini, Joanne E., Schödel, Florian, Pajon, Rolando, Zhou, Honghong, Das, Rituparna, Miller, Jacqueline · 2021 · medRxiv
PreprintCited by 21

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Following emergency use authorization in December 2020, the Coronavirus Efficacy (COVE) trial was amended to an open-label phase, where participants were unblinded and those randomized to placebo were offered vaccination. Emergence of the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with increased incidences of coronavirus disease 2019 (Covid-19) among unvaccinated and vaccinated persons. This exploratory analysis evaluated the incidence and genetic sequences of Covid-19 cases in the ongoing COVE trial during the open-label phase, with a focus on July-August 2021, when delta-variants surged in the US. Methods: Covid-19 cases were identified in participants initially randomized to mRNA-1273 (vaccinated from July-December 2020) and those initially randomized to the placebo (vaccinated December 2020-April 2021) who received at least one dose and were SARS-CoV-2-negative at baseline in the modified-intent-to-treat population were analyzed. Included were Covid-19 cases occurring after 26-Mar-2021 with positive RT-PCR results in nasopharyngeal samples (central lab test) and reported Covid-19 symptoms. Genetic sequencing of Covid-19 cases was also performed. Results: There were 14,746 participants in the earlier mRNA-1273 (mRNA-1273e) group and 11,431 in the later placebo-mRNA1273 (mRNA-1273p) group. Covid-19 cases increased from the start of the open-label phase to July-August 2021. During July and August, 162 Covid-19 cases occurred in the mRNA-1273e group and 88 in the mRNA-1273p group. Of the cases sequenced, 144/149 [97%]) in the mRNA-1273 and 86/88 (99%) in the mRNA-1273p groups were attributed to delta. The incidence rate of Covid-19 was lower for the mRNA-1273p (49.0/1000 person-years) versus mRNA-1273e (77.1/1000 person-years) group [36.4% (95% CI 17.1%-51.5%) reduction]. There were fewer severe Covid-19 cases in the mRNA-1273p (6; 6.2/1000 person-years) than mRNA-1273e (13; 3.3/1000 person-years) [46.0% (95% CI −52.4%-83.2%) reduction]. Three Covid-19 related hospitalizations occurred with two resulting deaths in the mRNA-1273e group. Conclusion: Incidence rates of Covid-19 and severe Covid-19 were lower during the months when delta was the dominant variant (July/August 2021) among COVE participants vaccinated more recently. Analysis of COVID-19 cases from the open-label phase of the COVE study is ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.09.17.21263624

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. El Sahly HM , Baden LR , Essink B , et al. Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase N Engl J Med 2021;In press.
  2. Nasreen S , He S , Chung H , et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv 2021:2021.06.28.21259420. · DOI

Cited by

See all 21

Metadata

Authors
Baden, L. R., El Sahly, H. M., Essink, B., Follmann, D., Neuzil, K. M., August, A., Clouting, H., Fortier, G., Deng, W., Han, S., Zhao, X., Leav, B., Talarico, C., Girard, B., Paila, Y. D., Tomassini, J. E., Schödel, F., Pajon, R., Zhou, H., Das, R., & Miller, J.
Venue
medRxiv
Publisher
openRxiv
Published
2021-09-22
OpenAlex
W3199911956
Cited by
21
References
4
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.